🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchMonthly semaglutide depot formulation — my results so far Page 5

Monthly semaglutide depot formulation — my results so far

tony_orlando Mon, Jul 22, 2024 at 3:23 PM 39 replies 2,686 viewsPage 5 of 8
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Jul 30, 2024 at 10:33 PM#21
labquiet_amy said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

This is where I part company with the consensus forming above. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

48 21paul_denver, TinaHashiRN, robert_kc and 45 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Aug 2, 2024 at 5:32 PM#22
labquiet_amy said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

49 22andrew_nyc, Dr.EndoEP, GraceAZ_72 and 46 others
Reply Quote Save Share Report
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Aug 5, 2024 at 12:30 PM#23
labquiet_amy said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

That reframing is the part I needed. Taking it to my next appointment.

50 23A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 47 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Aug 8, 2024 at 7:26 AM#24

Adding the clinical framing, because it changes how the question reads. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

1 24Dr.BariatricHTX
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Aug 11, 2024 at 2:21 AM#25
Dr.EndoEP said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Aug 11, 2024 at 5:21 AM
2 0amy_econ_NJ, bbq_ray_KC
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register